The effect of mu-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation (Q38349920)

2 September 2017

The effect of mu-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation (English)

1 reference

2 September 2017

1 reference

Shah S

1

1 reference

2 September 2017

Duttaroy A

2

1 reference

2 September 2017

Chen BT

3

1 reference

2 September 2017

Carroll J

4

1 reference

2 September 2017

Yoburn BC

5

1 reference

2 September 2017

1 January 1997

1 reference

2 September 2017

Brain Research Bulletin

1 reference

2 September 2017

42

1 reference

2 September 2017

6

1 reference

2 September 2017

479-484

1 reference

Intracerebroventricular treatment with an antisense oligodeoxynucleotide to kappa-opioid receptors inhibited kappa-agonist-induced analgesia in rats

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Selective inhibition of [D-Ala2, Glu4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Opioid peptide receptor studies. 1. Identification of a novel delta-opioid receptor binding site in rat brain membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

An antisense oligodeoxynucleotide to mu-opioid receptors inhibits mu-opioid receptor agonist-induced analgesia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Therapeutic Applications of Oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

The effect of intrinsic efficacy on opioid tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Intrathecal morphine in mice: a new technique

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Genomic structure analysis of promoter sequence of a mouse mu opioid receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Antisense oligodeoxynucleotide to a delta-opioid receptor given intrathecally blocks i.c.v. administered beta-endorphin-induced antinociception in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Antisense oligodeoxynucleotide to a delta-opioid receptor selectively blocks the spinal antinociception induced by delta-, but not mu- or kappa-opioid receptor agonists in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Chronic opioid antagonist treatment: assessment of receptor upregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

Naltrexone-induced opiate receptor supersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2896%2900375-9

7 January 2021

10.1016/S0361-9230(96)00375-9

Identifiers

DOI

1 reference

2 September 2017

1 reference